Tramadol - Valeant

Drug Profile

Tramadol - Valeant

Alternative Names: BVF-127; BVF-324; Ralivia; RWJ-26898-002; Tramadol ER; Tramadol ODT; Tramadol RD; Ultram; Ultram ER

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Biovail Corporation
  • Developer Valeant Pharmaceuticals International
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Opioid receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Discontinued Premature ejaculation

Most Recent Events

  • 08 Mar 2016 Biomarkers information updated
  • 31 Aug 2011 First generic equivalent approved in USA
  • 22 Nov 2010 Discontinued - Phase-III for Premature ejaculation in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top